Department of Obstetrics and Gynecology, School of Medicine, Mersin University, Mersin, Turkey.
Fertil Steril. 2010 Mar 1;93(4):1179-84. doi: 10.1016/j.fertnstert.2008.11.030. Epub 2009 Feb 6.
To observe the effects of ganirelix on controlled ovarian stimulation and intrauterine insemination (COS/IUI) cycles in women with polycystic ovary syndrome (PCOS).
Prospective, randomized, controlled clinical study.
An academic clinical research center.
PATIENT(S): Women with PCOS and anovulatory infertility undergoing COS/IUI.
INTERVENTION(S): Recombinant FSH therapy was started on day 3. In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration. In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
MAIN OUTCOME MEASURE(S): Pregnancy rates, serum E(2), P, and LH levels, and follicle numbers at hCG day, prevalence of premature luteinization, and cost of stimulation.
RESULT(S): Serum E(2), P, and LH levels were significantly lower in the ganirelix group. Although premature luteinization and cycle cancellation was encountered less in the ganirelix group, the pregnancy rates per cycle were similar (15.4% vs. 10.7%). Patients would pay 6,153 dollars more for each pregnancy when using ganirelix.
CONCLUSION(S): Gonadotropin-releasing hormone antagonist resulted in more monofollicular development, less premature luteinization, and less cycle cancellation in IUI cycles of patients with PCOS; however, the cost of stimulation increased without an improvement in pregnancy rates.
观察 GnRH 拮抗剂（加尼瑞克）对多囊卵巢综合征（PCOS）患者控制性卵巢刺激（COS）和宫腔内人工授精（IUI）周期的影响。
前瞻性、随机、对照临床研究。
某学术临床研究中心。
PCOS 伴排卵障碍性不孕，行 COS/IUI。
于月经第 3 天开始给予重组 FSH 治疗。对照组（n=47）继续治疗至 hCG 日，GnRH 拮抗剂组（n=42）当主导卵泡≥14mm 时添加加尼瑞克。
妊娠率、血清 E2、P 和 LH 水平、hCG 日卵泡数、早发 LH 峰发生率和刺激费用。
加尼瑞克组血清 E2、P 和 LH 水平显著降低。尽管加尼瑞克组早发 LH 峰和周期取消发生率较低，但周期妊娠率相似（15.4%比 10.7%）。使用加尼瑞克每个妊娠的成本将增加 6153 美元。
GnRH 拮抗剂可导致 PCOS 患者 IUI 周期中卵泡发育更单一、早发 LH 峰发生率更低、周期取消更少；但刺激费用增加，妊娠率无提高。
